Finance, Grants, Deals

Gates partners with Immunocore

The Bill & Melinda Gates Foundation is to invest up to $40 million in Immunocore Ltd to support the development of the company’s T cell receptor technology (TCR) for infectious disease. The UK company already has partnerships exploring TCRs against cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Genenta raises €7 million in Series B round

The Italian gene therapy company, Genenta Science srl, has raised €7 million in a Series B financing round to support development of a second tumor indication for its technology platform in addition to multiple myeloma. The funding was announced on 13 September.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Italy

Merck to acquire Rigontec

Merck & Co Inc is to acquire Rigontec GmbH of Germany in order to strengthen its portfolio of immuno-oncology compounds led by pembrolizumab. Rigontec has assets that target the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Nightstar plans $86 million US offering

Nightstar Therapeutics Ltd plans to raise up to $86 million in an initial public offering (IPO) of its shares on Nasdaq to advance its portfolio of gene therapies to treat rare inherited retinal diseases. A registration document was filed with the US Securities and Exchange Commission on 31 August.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Gilead to acquire Kite for $11.9 billion

Gilead Sciences Inc has made a dramatic entry to the field of regenerative medicine with an agreed bid for Kite Pharma Inc which has a portfolio of engineered cell therapies, the most advanced of which is under review in both the US and the EU.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Macrophage increases Series A financing

Macrophage Pharma Ltd has topped up a Series A financing round announced in January with an investment from Merck Ventures BV, a subsidiary of Merck KGaA. The size of the investment is reportedly £3 million, bringing the total raised in the A round up to £12 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

German mRNA company partners with AZ

A Munich-area company specialising in messenger RNA (mRNA) technology has entered into a drug discovery deal with AstraZeneca Plc. Ethris GmbH will receive €25 million upfront, plus research funding, to develop therapies for respiratory diseases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

GSK enters into second AI drug discovery deal

GlaxoSmithKline Plc has entered into a collaboration with Insilico Medicine Inc to use the US company’s artificial intelligence (AI) platform to discover new drugs. This is its second AI deal in less than two months.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Overallotment exercised for Zealand Pharma’s IPO

Underwriters for the US initial public share offering of Zealand Pharma A/S have exercised an option to buy more shares, increasing proceeds for the Danish company to DKK 566.4 million ($89.4 million), up from DKK 492.5 million ($78.3 million) previously.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark

Zealand Pharma raises $78.3 million in Nasdaq IPO

Denmark’s Zealand Pharma A/S has raised DKK 492.5 million ($78.3 million) from its previously announced initial public share offering on Nasdaq in the US. The goal is to support the clinical development of two of its peptide therapeutics.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark

Syndicate content